Now CMO at CORXEL, Liang tells PharmExec he sees GLP-1s as a platform for heart, kidney and liver disease, with obesity only one piece of it.
Recap by typeshit. Full story at Pharmaceutical Executive.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
The American Academy of Ophthalmology reports that among patients with optic nerve strokes in both eyes, the second eye was hit faster on GLP-1s.
A look at how the rise of GLP-1 drugs is changing which research samples scientists are buying. Details are thin beyond the headline.
Loading…